As Capitol Hill readies itself for the August Recess, and as President Barack Obama demands that a bill reach his desk in the Oval Office by October, healthcare reform still finds itself in more-or-less the same quagmire as it did in 1993. We take a look at the chances of comprehensive reform this year and tackle the nitty-gritty of one of the most complex and polarising issues of Washington politics today.
Generational stereotypes are never easy to swallow, but when it comes to doctors and an investment in social media, the new generations of medical professionals are increasingly going online for both professional collaboration and patient support.
With increased investment in R&D largely failing to fill drug development pipelines, the pharma industry is looking to get more bang for its R&D buck by generating some return out of failed drug candidates and extra return out of others. Drug re-positioning has become a key strategy for pharmaceutical groups, and according to Datamonitor, this approach is set to become more frequently employed.
Getting a job in Clinical research or Regulatory Affairs can be tough at the best of times. Have you ever wondered how some people seem to know everybody and they are always the first to know what is happening in the industry and what roles are available?
Spanning one third of the globe's circumference and home to more than half of the world's population, the Asia Pacific region is incredibly diverse. This year's World Vaccine Congress Asia highlighted the enormous variation in the vaccine landscape in the region, owing to a myriad of political, cultural, economic and geographic differences.
Unless it paints the right picture you’re letting the side down!
In a depressed job market, an employer is likely to receive 50+ CVs per job advertised from 5 or more Preferred Agencies and many more from agencies who ‘piggy back’ in. So now, more than ever, your CV needs to stand out and be tailored to the role and client and submitted by an agency with valid access.
Avril Horn PhD
Datamonitor attended the American Society of Clinical Oncology's 45th Annual Meeting in Orlando, Florida, to assess the key highlights of the conference. A number of promising presentations evaluated the potential of currently marketed agents to successfully combine with conventional chemotherapy in indications with persistent high unmet needs.
Dr Wolfgang Wein, Executive Vice-President of Merck Serono’s Oncology Business comments on the recent final appraisal determination by NICE paving the way for its leading oncology product Erbitux to benefit UK mCRC patients.
Olwen Glynn Owen - Pharmiweb Field reporter
Despite the pharmaceutical industry's evolving business model in response to growing regulatory constraints, the sector is facing unprecedented challenges caused by the economic downturn and President Obama's planned overhaul of the US healthcare system. To continue on its journey towards 'Pharma 2.0', the industry must balance the more pressing short term issues against longer term trends
Priyanka Adhikari - Datamonitor
The Department of Health is determined to improve commissioning, and it will do whatever it takes to make it happen. That is the message that senior departmental officials sent to practice based commissioners last week at a National Association of Primary Care conference in London.
The time has arrived for primary care trusts to shed their provider functions, and it is causing considerable angst in the community services sector. It was inevitable that sooner or later, the split would have to happen, but now the race is on to decide what organisation model they want to adopt: foundation trust or social enterprise?
Senior Department of Health executives, speaking at a recent NHS Alliance Conference, suggested that the NHS has two years left before it starts to the credit crunch’s bite – maybe less if there is an election in a years’ time. But this should not be cause complacency in the health sector. The message is, invest wisely now so that you are well prepared for the fallow times ahead.
The growing incidence of diseases and conditions related to aging is creating pockets of opportunity for pain management. These opportunities include the expanding use of prescription NSAIDs as second-line therapies for chronic pain and an increase in off-label prescribing. As populations and indications evolve, so too is the pain management sector.
Applied Data Research
In this edition of StrategicEdge, CBR Pharma Insights discusses the current trends and opportunities that exist in marketing to consumers as the age of TiVo, DVRs, and cost constraints point the industry towards creative uses of the internet and other e-technologies.
CBR Pharma Insights
The recent outbreak of influenza A (H1N1) infection, previously referred to as swine flu, has thrown the spotlight on governments around the world and their ability to manage a pandemic. In the UAE, customers are currently finding it difficult to source antivirals but, with Dubai seen as a hub for international travel, the government has stockpiles ready for distribution should an outbreak occur.
At least 1.3 billion people worldwide lack access to the most basic healthcare, with this burden being greatest in countries overwhelmed by poverty. Since the gap between rich and poor is widening, the Global Health Education Foundation (GHEF: www.globalhef.org) has been set up to tackle worsening disparities in healthcare.
Dr John Wei
The inspiration for this article came to me when watching an interview with Mr N R Narayanmurthy, Chief Mentor at Infosys. I was particularly taken by his control and poise; clearly, someone with years of training and experience in being interviewed can be completely at ease in such a stressful situation, but it made me think about how we can all improve our own techniques and create that vital positive first impression.
As part of the UK government's drive to save over GBP2 billion in the NHS during 2010-11, GBP550m will be cut from the prices of branded drugs as a result of the revised Pharmaceutical Price Regulation Scheme. With the volume of branded drugs having remained flat over the last four years, total sales of the UK branded pharmaceutical industry are forecast to decline from 2009 onwards.
The latest outbreak of influenza virus H1N1 “swine flu” is now widely tipped to cause a global pandemic of unknown severity. Previously, the influenza vaccine community discussed the theoretical limitations of current technologies and capacity. Now they are faced with the reality of these limitations. VacZine Analytics believes H1N1 must change the science of influenza vaccines.
VacZine Analytics Group
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her